FAP and neoplasm: The antitumor effects of antibody–drug conjugates targeting FAP have been observed [8] and a phase I study of AVA6000, a peptide drug conjugate that releases doxorubicin in the tumor microenvironment of FAP-positive solid tumors, showed antitumor effects while reducing systemic exposure to doxorubicin [9].